The randomised evidence that glucagon-like peptide-1 (GLP-1) receptor agonists reduce alcohol consumption has, until this year, rested mostly on preclinical models, observational cohorts and pharmacoepidemiology. Two randomised trials reported in 2026 have begun to change that picture. Neither changes the licensed position in the UK, and one of them failed its primary endpoint. Both are worth reading precisely.
The oral semaglutide trial
Schacht and colleagues randomised 50 treatment-seeking adults with moderate-to-severe alcohol use disorder (AUD) to oral semaglutide or placebo in a Phase 2, double-blind, parallel-arm trial. The design escalated oral semaglutide from 3 mg per day for four weeks to 7 mg per day for a further four weeks, and combined laboratory cue-reactivity testing with Timeline Follow-Back naturalistic drinking assessment. Those figures describe the trial protocol, not a schedule for use.
The primary endpoint, laboratory-based alcohol cue-induced craving on a visual analogue scale at week six, did not separate from placebo. Drinks per calendar day, one of two preregistered key secondary endpoints, also did not separate. On the other key secondary endpoint the groups did diverge: heavy drinking days fell significantly relative to placebo over the final four weeks of treatment (P = .008) and across the whole treatment period (P = .035).
A cluster of secondary and exploratory outcomes moved in the same direction: fewer drinks per drinking day, lower Penn Alcohol Craving Scale scores, improved PROMIS alcohol-consequences scores, and a higher likelihood of reducing at least one level on the WHO risk-drinking scale, at 81.0 per cent versus 53.8 per cent.
Why the endpoint split matters
The trial is a clean illustration of how much the choice of endpoint and measurement window shapes a headline. Laboratory cue-elicited craving is a laboratory proxy; heavy drinking days is a naturalistic measure closer to clinical relevance. A trial can fail the first and still move the second. That is a finding about measurement as much as about semaglutide, and it is why the result reads as hypothesis-generating rather than settled. The sample was 50 adults, small and not powered to detect modest effects.
A separate, longer randomised trial of once-weekly injectable semaglutide in adults with alcohol use disorder and obesity has also reported reductions in heavy drinking days. Read together with the oral trial, the pattern is consistent enough to justify larger, adequately powered studies, and not yet strong enough to describe semaglutide as a treatment for AUD.
The UK position
No GLP-1 receptor agonist is licensed in the UK for alcohol use disorder. Semaglutide products are prescription-only medicines authorised for type 2 diabetes and for weight management under the Human Medicines Regulations 2012, and their supply is governed by the Medicines Act 1968 and by the MHRA. Use outside those indications is a matter for a prescriber. The MHRA continues to monitor the class through the Yellow Card scheme, including the pancreatitis signal set out in its 29 January 2026 Drug Safety Update.
What this does not mean
This article describes research findings in a clinical-trial population. It is not a statement that any peptide treats, cures or prevents alcohol use disorder, and it is not a guide to use. All compounds referenced here are described for research and reference purposes only; nothing on this page is consumption or dosing advice.
Evidence grade for GLP-1 receptor agonists in alcohol use disorder: Limited. Two small randomised trials with a split primary and secondary endpoint profile, no Phase 3 data, and no licensed indication.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.